	US 12,344,671 B2
	Blood-brain barrier transmigrating therapeutic compounds and uses thereof
Hung Fang, Ottawa (CA); Danica Stanimirovic, Ottawa (CA); Arsalan Haqqani, Kanata (CA); Will Costain, Ottawa (CA); and Gregory Hussack, Ottawa (CA)
Assigned to National Research Council of Canada, Ottawa (CA)
Appl. No. 17/050,075
Filed by National Research Council of Canada, Ottawa (CA)
PCT Filed Apr. 23, 2019, PCT No. PCT/CA2019/050499 § 371(c)(1), (2) Date Oct. 23, 2020, PCT Pub. No. WO2019/204912, PCT Pub. Date Oct. 31, 2019.
Claims priority of provisional application 62/661,869, filed on Apr. 24, 2018.
Prior Publication US 2021/0253715 A1, Aug. 19, 2021
Int. Cl. A61K 47/68 (2017.01); A61P 21/00 (2006.01); C07K 14/765 (2006.01); C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2863 (2013.01) [A61K 47/6843 (2017.08); A61P 21/00 (2018.01); C07K 14/765 (2013.01); A61K 9/0019 (2013.01); A61K 2039/505 (2013.01)]

23 Claims

1. A fusion protein comprising

an antibody or a fragment thereof, operable to transmigrate the blood-brain barrier (BBB), that selectively binds IGF1R,

a therapeutic polypeptide for the treatment of a lysosomal storage disease (LSD), and

a serum half-life extending element selected from the group consisting of a human serum albumin and an albumin targeting moiety,

wherein the antibody or fragment thereof comprises

a complementarity determining region (CDR) 1 sequence EYPSNFYA (SEQ ID NO:6); CDR2 sequence VSRDGLTT (SEQ ID NO:7); and CDR3 sequence AIVITGVWNKVDVNSRSYHY (SEQ ID NO:8); or

a complementarity determining region (CDR) 1 sequence GRTIDNYA (SEQ ID NO:11); CDR2 sequence IDWGDGGX, where X is A or T (SEQ ID NO: 12); and CDR3 sequence AMARQSRVNLDVARYDY (SEQ ID NO: 13).